
    
      Phase Ia of this study is a dose escalation and safety expansion phase, investigating NG-350A
      administration by intratumoural (IT) injection and intravenous (IV) infusion. Phase Ib of
      this study will investigate efficacy in patients with specific epithelial tumour types.
    
  